Now That Fluor Is Done Selling Its Stake in NuScale Power, Is It Time to Buy the Next-Gen Nuclear Company?

NuScale remains the only SMR developer with NRC standard design approval, and the agency’s mid-2025 approval of its uprated 77-MWe module strengthens its first-mover advantage. However, Fluor has fully exited after selling an estimated $2.43 billion stake, removing an overhang but highlighting that NuScale is still years from commercial operations and has only one project underway in Romania targeting 2033. The setup is constructive for the nuclear SMR theme, but the stock remains highly volatile and dependent on securing additional firm agreements.

Analysis

The key market dynamic is not the NRC approval itself, but the mismatch between a long-duration commercialization story and a stock that already priced in near-perfect execution. The recent collapse likely reflects the removal of a technical seller, but that does not automatically create incremental fundamental demand; if anything, it shifts the tape from supply-driven weakness to event-driven volatility. In this setup, SMR behaves more like a binary option on contracting milestones than a traditional industrial equity.

The second-order winner is the broader nuclear enablement stack, not necessarily the module designer. If SMR adoption accelerates, value should accrue to EPC, specialty components, and fuel-cycle names that can monetize multiple projects regardless of which reactor architecture wins. Conversely, a slow rollout hurts the “story stock” cohort most because higher discount rates and long-dated cash flows punish any schedule slippage; every year of delay materially reduces present value and keeps financing risk elevated.

The market is likely underpricing governance and funding risk relative to technology risk. A small customer-intermediary like ENTRA1 creates execution leverage, but it also adds counterparty fragility and makes the commercial funnel look thinner than headline partnerships suggest. The real catalyst is not another approval but a second or third firm deployment commitment; absent that, the stock can remain trapped in a sentiment band even if the seller overhang is gone.

Contrarian view: the recent drawdown may be less a capitulation bottom than a de-rating toward a more realistic probability-weighted outcome. If the market starts treating SMR as a platform with optionality rather than a near-term growth compounder, multiples could compress further before any true operating inflection. That makes the best risk/reward likely a staged entry or a call-spread expression rather than outright equity.

Key Decisions for Investors

• Avoid chasing SMR common stock immediately; wait 30-60 days for post-sale stabilization and only add on a confirmed second deployment commitment or financing milestone, because the next catalyst is likely binary rather than linear.
• For aggressive exposure, buy SMR Jan-2027 call spreads instead of stock to express upside to a multi-contract adoption scenario while capping downside to premium paid; use this only if willing to absorb high volatility and low probability of early monetization.
• Pair trade: long FLR on any post-divestiture pullback against a small short SMR basket hedge, as capital redeployment and removal of the overhang should favor the diversified engineering name over the pre-revenue platform story over the next 3-6 months.
• Watch for a rotation into nuclear infrastructure suppliers and EPC names over the next 1-2 quarters; prefer businesses with nearer-term revenue recognition and lower dependency on one architecture over SMR pure plays.
• If SMR rallies hard on headline momentum without fresh contracts, fade strength with a tight stop, since the stock remains highly sensitive to sentiment and could retrace quickly once retail momentum fades.